RxDoctor Payments Data

Eric Grubman, MD

Clinical Cardiac Electrophysiology · North Haven, CTNPI 1124039490

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (53.3%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Medtronic accounts for 86.5% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $14,512 and has fallen 80.6% since, to $2,810 in 2025.

$32,054in general payments, 2019–2025

Across 135 payments — averaging $237.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$28K
  • Boston Scientific$2K
  • Biosense Webster, Inc.$1K
  • Abbott$1K
  • Biotronik Inc.$43
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$3
$195,520in research payments, 2019–2025

Across 71 payments — averaging $2753.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$196K

What the payments were for

  • Consulting fees$3,76312%
  • Speaking & faculty fees$17,10053%
  • Travel & lodging$7,71224%
  • Food & beverage$3,47911%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,054 in reported general payments places this provider in the 70th percentile of 47 clinical cardiac electrophysiology providers in Connecticut.

See all clinical cardiac electrophysiology providers in Connecticut

Medicare billing

Part B allowed, 2024
$273,740
Medicare patients
1,845
Services billed
4,532

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban49$76,909
MultaqDronedarone Hcl34$62,223
XareltoRivaroxaban13$19,418
Diltiazem 24hr Er (Cd)Diltiazem Hcl30$2,124
Amiodarone Hcl50$1,095
Metoprolol Succinate88$992
Rosuvastatin Calcium21$359
Atorvastatin Calcium30$286
Isosorbide Mononitrate ErIsosorbide Mononitrate18$242
SotalolSotalol Hcl20$155
Losartan Potassium20$95
Cephalexin16$84
Furosemide15$68
Metoprolol Tartrate26$67
Hydrochlorothiazide16$29

Paid to pharmacies, not to this prescriber.

Other clinical cardiac electrophysiology in North Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →